Bright Minds arranges $10M (U.S.) public offering

Executive Summary

• Bright Minds Biosciences Inc. has launched a public offering of common shares and prefinanced warrants for aggregate gross proceeds of $100 million (U.S.).
• The company intends to use the net proceeds to finance future clinical trials for drug candidates targeting absence seizures, Developmental and Epileptic Encephalopathy (DEE), and Prader-Willi syndrome, as well as initiate Phase 1 trials for BMB-105 and fund general R&D and working capital.
• Jefferies, TD Cowen, Piper Sandler & Co., and Cantor Fitzgerald are acting as joint bookrunning managers, with a 30-day over-allotment option for up to 15% of the shares.

Key Details

• Offering Structure: Public offering of common shares and, in lieu of common shares, prefinanced warrants to purchase common shares.
• Gross Proceeds: $100 million (U.S.).
• Use of Proceeds:
  • Finance future clinical trials for drug candidates for absence seizures, DEE, and Prader-Willi syndrome.
  • Initiation of Phase 1 clinical drug trials for BMB-105.
  • Additional research and development work on earlier phase programs.
  • General corporate and working capital purposes.
• Underwriters/Managers: Jefferies, TD Cowen, Piper Sandler & Co., and Cantor Fitzgerald acting as joint bookrunning managers.
• Over-Allotment Option: The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the common shares issued in the offering.
• Regulatory Filing: Shelf registration statement on Form F-3 filed with the U.S. SEC, declared effective on September 2, 2025.
• Distribution Channel: Offering made solely by means of a prospectus and prospectus supplement forming part of the registration statement.

Notable Quotes

• No direct quotes from management were included in the provided text.